|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.50 SEK | -9.38% |
|
-41.41% | -53.90% |
| Jun. 10 | 12 stocks hit new 52-week lows on the Stockholm Stock Exchange so far today | FW |
| Jun. 09 | 14 stocks hit new 52-week lows on the Stockholm Stock Exchange so far today | FW |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Development of Protein Kinase Inhibitors for Targeted Cancer Treatment | - | - | - | - | 2.47M | |||||
Total Assets | 623M | 585M | 765M | 796M | 769M | |||||
Interest Expense | -4K | -12K | -675K | -1.93M | -16.85M | |||||
Income Tax Expense | - | - | -17K | -151K | -104K | |||||
CAPEX | -95.96M | -128M | -2.69M | -4.38M | - | |||||
EBT | -96.7M | -132M | -180M | -286M | -172M | |||||
D&A | 8.87M | 9.53M | 9.19M | 8.55M | 5.58M | |||||
Operating Income | -97.95M | -133M | -182M | -287M | -157M | |||||
Net Income | -96.7M | -132M | -180M | -286M | -171M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Sweden | - | - | - | - | 2.47M | |||||
Total Assets | 623M | 585M | 765M | 796M | 769M | |||||
Interest Expense | -4K | -12K | -675K | -1.93M | -16.85M | |||||
Income Tax Expense | - | - | -17K | -151K | -104K | |||||
D&A | 8.87M | 9.53M | 9.19M | 8.55M | 5.58M | |||||
CAPEX | -95.96M | -128M | -2.69M | -4.38M | - | |||||
Net Income | -96.7M | -132M | -180M | -286M | -171M | |||||
EBT | -96.7M | -132M | -180M | -286M | -172M | |||||
Operating Income | -97.95M | -133M | -182M | -287M | -157M |
- Stock Market
- Stocks
- XSPRAY Stock
- Financials Xspray Pharma AB
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
